Therma Bright (TSE:THRM) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Therma Bright’s distribution partners in the U.S. have achieved rapid Medicare and Medicaid reimbursement approvals for their Venowave VW5 device in under 60 days. This achievement is expected to accelerate commercialization efforts as it impresses medical networks and sets a roadmap for increased sales.
For further insights into TSE:THRM stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money